After more than a decade on the market, Takeda Pharmaceutical Co. Ltd.’s Iclusig (ponatinib) looks set to become standard of care in the first-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults, based on data from a Phase III trial comparing it against a targeted therapy used off-label in that indication, imatinib (Novartis AG’s Gleevec and generics).
Takeda presented data from the Phase III PhALLCON trial on 15 February at the American Society of Clinical Oncology’s monthly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?